Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia

American Journal of Hematology
Irene M GhobrialJeffrey Matous

Abstract

This study aimed to determine the activity and safety of weekly bortezomib and rituximab in patients with untreated Waldenström Macroglobulinemia (WM). Patients with no prior therapy and symptomatic disease were eligible. Patients received bortezomib IV weekly at 1.6 mg/m(2) on days 1, 8, 15, q 28 days × 6 cycles, and rituximab 375 mg/m(2) weekly on cycles 1 and 4. Primary endpoint was the percent of patients with at least a minor response (MR). Twenty-six patients were treated. At least MR was observed in 23/26 patients (88%) (95% CI: 70-98%) with 1 complete response (4%), 1 near-complete response (4%), 15 partial remission (58%), and 6 MR (23%). Using IgM response evaluated by nephlometry, all 26 patients (100%) achieved at least MR or better. The median time to progression has not been reached, with an estimated 1-year event free rate of 79% (95% CI: 53, 91%). Common grade 3 and 4 therapy related adverse events included reversible neutropenia in 12%, anemia in 8%, and thrombocytopenia in 8%. No grade 3 or 4 neuropathy occurred. The combination of weekly bortezomib and rituximab exhibited significant activity and minimal neurological toxicity in patients with untreated WM.

References

Jul 1, 1993·The American Journal of Medicine·M A DimopoulosM J Keating
Jan 7, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M A DimopoulosM Dalakas
Sep 3, 2003·European Journal of Haematology·G MetzgerothJ Hastka
Nov 7, 2003·The Lancet Oncology·Irene M GhobrialRafael Fonseca
Apr 30, 2004·Current Treatment Options in Oncology·Irene M Ghobrial, Thomas E Witzig
Sep 16, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S P TreonK C Anderson
Oct 16, 2004·The Korean Journal of Internal Medicine·Soo-Mee BangNoe Kyeong Kim
Dec 16, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S P TreonUNKNOWN Waldenström's Macroglobulinemia Clinical Trials Group
Mar 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Meletios A DimopoulosSteven P Treon
Mar 30, 2005·Clinical Lymphoma·Steven P TreonJean-Paul Fermand
Mar 14, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christine I ChenUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Jun 5, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Steven P TreonAshraf Badros
Mar 13, 2008·Blood·Xavier LeleuIrene M Ghobrial
Dec 3, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Meletios Athanasios DimopoulosSteven P Treon
Dec 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Xavier LeleuSteven P Treon
Feb 7, 2009·Blood·Pierre MorelGiampaolo Merlini
Jun 10, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Steven P TreonIrene M Ghobrial
Jul 21, 2009·Blood·Steven P Treon

❮ Previous
Next ❯

Citations

Jun 19, 2013·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Lucy S Hodge, Stephen M Ansell
Aug 30, 2011·Bone Marrow Transplantation·M A GertzS M Ansell
Feb 7, 2013·Leukemia·C Buske, V Leblond
Oct 23, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C BuskeUNKNOWN ESMO Guidelines Working Group
Apr 27, 2011·Current Opinion in Hematology·Ghayas C IssaIrene M Ghobrial
Jun 27, 2013·Journal of Clinical and Experimental Hematopathology : JCEH·Giovanni CarulliMario Petrini
Oct 29, 2011·Clinical Investigation·Ghayas C IssaAldo M Roccaro
Apr 26, 2014·Immunotherapy·Laetitia Souchet-CömpainStéphanie Nguyen
Sep 13, 2014·Hematology/oncology Clinics of North America·Steven P TreonGiampaolo Merlini
Aug 7, 2012·Leukemia & Lymphoma·Morie Gertz
Nov 12, 2010·Leukemia & Lymphoma·Morie A Gertz
Jul 22, 2015·Expert Review of Anticancer Therapy·Rajshekhar ChakrabortyMorie A Gertz
Jan 11, 2014·Expert Review of Hematology·Ilyas SahinIrene M Ghobrial
Sep 30, 2014·Expert Opinion on Pharmacotherapy·Prithviraj BoseSteven Grant
Jan 29, 2016·Expert Opinion on Pharmacotherapy·Solomon Graf, Ajay Gopal
Nov 26, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M A DimopoulosI M Ghobrial
Apr 9, 2013·Clinical Lymphoma, Myeloma & Leukemia·Meletios A DimopoulosEfstathios Kastritis
Nov 9, 2011·Clinical Lymphoma, Myeloma & Leukemia·Irene M GhobrialAldo M Roccaro
Dec 7, 2013·Clinical Lymphoma, Myeloma & Leukemia·Houry LeblebjianIrene Ghobrial
Apr 2, 2011·Clinical Lymphoma, Myeloma & Leukemia·Giovanni PalladiniGiampaolo Merlini
Apr 18, 2015·Blood Reviews·Prashant KapoorPhilip R Greipp
Mar 25, 2014·Frontiers in Immunology·Laura Oliva, Simone Cenci
Nov 9, 2016·Best Practice & Research. Clinical Haematology·Rajshekhar ChakrabortyMorie A Gertz
Dec 13, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Irene M Ghobrial
Apr 12, 2017·Leukemia & Lymphoma·Véronique LeblondUNKNOWN French Innovative Leukemia Organization (FILO)
Jun 9, 2017·Expert Review of Hematology·Giulia BenevoloUmberto Vitolo
May 18, 2018·Expert Opinion on Drug Safety·Ramón García-SanzMaría Eugenia Sarasquete
Apr 11, 2018·British Journal of Haematology·Laurence SimonVéronique Leblond
Sep 8, 2018·Hematological Oncology·Alessandra TedeschiMarzia Varettoni
Dec 10, 2017·Hematology·Jorge J Castillo, Steven P Treon
Dec 5, 2017·Journal of Market Access & Health Policy·Andrea AielloLuca Laurenti
Jan 22, 2020·Leukemia & Lymphoma·Iuliana Vaxman, Morie Gertz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Irene M GhobrialJeffrey Matous
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Steven P TreonIrene M Ghobrial
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Irene M GhobrialThomas E Witzig
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Meletios DimopoulosGerasimos Pangalis
© 2021 Meta ULC. All rights reserved